Introduction {#s1}
============

Patients with both major forms of diabetes suffer from insufficient functional pancreatic β-cell mass, making therapies that expand β-cell mass a targeted goal of diabetes research ([@B1]). Furthermore, glucose is an important natural mitogen of β-cells both in vitro and in vivo ([@B2]--[@B5]). Glucose acts as a systemic driver of β-cell mass in response to increased insulin demand. Glucose metabolism triggers insulin secretion but also serves as a mechanism to signal cell proliferation. Thus, glucose-stimulated β-cell proliferation is an essential component of adaptive β-cell expansion and long-term glucose homeostasis ([@B5]). Human β-cells proliferate at much slower rates than rodent β-cells ([@B1],[@B6]). Nonetheless, glucose metabolism drives human β-cell proliferation both in vitro and in vivo ([@B4],[@B7]). Thus, understanding mechanisms of glucose-stimulated β-cell proliferation provides opportunities to develop therapies to expand β-cell mass.

We demonstrated that carbohydrate response element--binding protein (ChREBPα, gene symbol *MLXIPL*) is required for glucose-stimulated proliferation of rodent and human β-cells ([@B4]). Important for this study, overexpression of ChREBPα augments glucose-stimulated proliferation of both rodent and human β-cells. ChREBPα is a transcription factor that is activated by increased glucose metabolism and binds to carbohydrate response elements in order to drive the expression of target genes ([@B8]). Numerous posttranslational events modify the cellular localization, DNA binding activity, and transactivation activity of ChREBPα, making it an effective transcriptional sensor of increased glucose flux ([@B9]). ChREBP exists as two major isoforms ([@B10]). ChREBPα is the "classic" full-length, glucose-regulated form. ChREBPβ is an alternatively spliced isoform that lacks the low glucose inhibitory domain (which also contains nuclear export signals) and is unrestrained by low glucose, is constitutively nuclear, and is much more potent than its longer counterpart ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). ChREBPβ is induced by a carbohydrate response element (ChoRE) located near the start site of an alternative promoter for ChREBPβ. Thus induction of the β isoform leads to an autoregulated feed-forward loop: the newly synthesized ChREBPβ binds to the ChoRE on its own promoter (and other ChREBP target genes), leading to production of still more ChREBPβ. We recently found that the induction of ChREBPβ, from a nearly undetectable amount to a level comparable to that of ChREBPα, is required for glucose-stimulated proliferation ([@B11]). However, expression of ChREBPβ for too long and at too high a level, as may happen in response to diabetic hyperglycemia or through overexpression, results in β-cell death ([@B12]). By contrast, inducible overexpression of the full-length form of ChREBP (ChREBPα) does not induce cell death and has no effect on glucose-stimulated insulin secretion (GSIS) ([@B13]) (see [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). It is remarkable that overexpression of ChREBPα amplifies glucose-stimulated β-cell replication rates, without increasing apoptosis, in both rodent and human β-cells ([@B4]) (see [results]{.smallcaps}). This study was conducted to gain clarity on how ChREBPα augments glucose-stimulated proliferation of β cells.

The transcription factor nuclear factor erythroid 2--like 2 (Nrf2) mediates the expression of antioxidant enzyme genes and genes involved in intermediary metabolism, as well as mitochondrial biogenesis, acting through antioxidant response elements (AREs) ([@B14]). The antioxidant Nrf2 pathway has antiobesity and antidiabetic properties; it suppresses body weight gain when a high-calorie diet is consumed, increases plasma levels of fibroblast growth factor 21 in rodent models of obesity, and protects against diabetes complications (for a review, see \[[@B15]\]). Indeed, several Nrf2 activators have been under investigation in clinical trials for the treatment of diabetes ([@B16]).

In this study we demonstrate that ChREBPα initiates anabolic metabolism and increases mitochondrial mass and activity, at least in part, through activation of the Nrf2 pathway, thus augmenting glucose-stimulated β-cell proliferation. This process requires the induction of ChREBPβ. In addition, we show---to our knowledge for the first time---that activation of Nrf2 is necessary for glucose-stimulated proliferation of rodent and human β-cells and that overexpression of Nrf2 is sufficient to drive human β-cell proliferation.

Research Design and Methods {#s2}
===========================

Antibodies and Reagents {#s3}
-----------------------

Antibodies for PGC1α, PGC1β, and Nrf2 were purchased from Santa Cruz Biotechnology (Dallas, TX). Antibodies for Nrf1 and BrdU were purchased from Abcam (Cambridge, MA). The ChREBP antibody (COOH-terminal) was obtained from Novus Biologicals (Littleton, CO). Antibodies to β-actin and Flag were obtained from Sigma-Aldrich (St. Louis, MO). The baculovirus expressing mitochondrial red fluorescent protein (CellLight Mitochondria-RFP, BacMam 2.0), DAPI, and all the Alexa fluorophore--tagged secondary antibodies were purchased from Life Technologies (Carlsbad, CA). Human Keap1 adenovirus was obtained from Vigene Biosciences, Inc. (Rockville, MD).

Mice and Mouse Islet Isolation {#s4}
------------------------------

A conditional targeting vector was produced through standard recombineering methods, with insertion of a *loxP* site 160 base pairs upstream from ChREBP exon 1b and a *loxP*, *frt*-flanked neo cassette 680 base pairs downstream from exon 1b. Germline-competent 129 W4 embryonic stem cells were transfected with the linearized targeting vector and screened through the use of long-range PCR. Two positive clones were expanded and injected into C57Bl/6J blastocysts to obtain chimeric mice (generated in the Transgenic Core Facility at Beth Israel Deaconess Medical Center). Chimeric mice were crossed with C57Bl/6J mice to generate offspring and to confirm germline transmission of the floxed ChREBP exon 1b. Mice carrying the floxed allele were crossed with mice expressing Flp1 recombinase (stock no. 003800; The Jackson Laboratory, Bar Harbor, ME) to remove the *frt*-flanked neo cassette. Mouse islets were isolated and cultured as previously described ([@B4]).

Cell Culture and Adenovirus {#s5}
---------------------------

INS1-derived 832/13 cells (henceforth referred to as INS1 cells) ([@B17]) were cultured as described previously ([@B18]). The proliferation assay, incorporating BrdU, was carried out with INS1 cells, as previously described ([@B11]). Islets were dispersed and cultured as previously described ([@B4]). Cells were transduced as previously described ([@B4]): transduction with serum-free RPMI medium containing 150--300 multiplicity of infection adenovirus for 2 h, with the adenoviral vectors encoding Flag-tagged wild-type ChREBPα (Ad.ChREBPα), Keap1 (Ad.Keap1), Nrf2 (Ad.Nrf2), and Cre (Ad.Cre), or either green fluorescent protein (GFP) (Ad.GFP) or LacZ (Ad.LacZ) adenovirus, used as controls. Adenoviral transduction lasted for 48 h before glucose treatment unless stated otherwise. To knock down Nrf2, cells transduced with Ad.LacZ or Ad.ChREBPα were transfected with rat Nrf2 small interfering RNA (siRNA) (catalog no. AM16708; Ambion). The Ad.Cherry-ChREBPβ adenovirus was made using the Gateway recombination system (Life Technologies) after subcloning a truncated mouse ChREBP cDNA (nucleotides 531--2,595) with Cherry cDNA in frame on the N-terminus into the pENTR vector, as described previously ([@B1]). Nrf2- and Keap1-expressing adenoviruses were purchased from Vector Biolabs.

Cell Proliferation {#s6}
------------------

INS1 cells were cultured on LabTek II chamber slides (Nunc, Rochester, NY). BrdU (10 μg/mL) was added during the last 40 min of incubation, and cells were fixed in 2% paraformaldehyde in PBS. Cells were immunostained using rat anti-BrdU antibody and Alexa594-labeled antirat antibody. Nuclei were stained with DAPI. Cells were imaged with a Zeiss Axioplan 2 microscope or either a Zeiss LSM510 or a Zeiss LSM880 confocal microscope. Proliferation in dispersed human islet cells was determined by Ki67 staining ([@B11]).

Immunofluorescent Staining {#s7}
--------------------------

INS1 cells were cultured on cell culture--treated Corning BioCoat coverslips (catalog no. 354087), and immunofluorescent staining and imaging were carried out as described above ([@B11]).

Human Islets {#s8}
------------

Human cadaveric islets received from the Integrated Islet Distribution Program were cultured as previously described ([@B4]). To knock down Nrf2 in human islet cells, dispersed human islet cells were transfected with a pooled Accell siRNA targeting Nrf2 (catalog no. E-003755--00; Dharmacon) through the use of a previously described method ([@B4]).

RT-PCR and Quantitative Real-time PCR {#s9}
-------------------------------------

Total RNA was extracted and RT-PCR was performed as previously described ([@B4]). To measure mitochondrial DNA in INS1 cells, DNA was extracted using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI). The sequences of primers used are listed in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1).

Immunoblotting {#s10}
--------------

Protein extracts were prepared and immunoblotted as previously described ([@B19]).

Determination of Mitochondrial Content {#s11}
--------------------------------------

INS1 cells were cotransduced with CellLight Mitochondria-RFP baculovirus and either Ad.LacZ or Ad.ChREBPα for 48 h, then were treated with the indicated glucose concentrations for 20 h. Dispersed human islet cells were treated with Ad.LacZ or Ad.ChREBPα and stained with MitoTracker Red CMXRos and immunostained for insulin. A TMRE-Mitochondrial Membrane Potential Assay Kit was obtained from Abcam. The antibody to Keap1 was obtained from Cell Signaling Technology (Danvers, MA). To measure mitochondrial DNA content, we used 100 ng DNA and primers to the [d]{.smallcaps}-loop region of the mitochondrial genome. GAPDH primers were used to normalize mitochondrial DNA abundance to genomic DNA abundance.

Determination of ATP Content and ATP-to-ADP Ratios {#s12}
--------------------------------------------------

To determine ATP content, cell extracts were passed through a filter (molecular weight cutoff 10 kDa), and the ATP content in the filtrate was determined using the ENLITEN ATP Assay System (Promega). ATP and ADP levels were determined using a kit (catalog no. ab65313; Abcam), according to the manufacturer's instructions.

Determination of Autophagy, Reactive Oxygen Species, and Cell Death {#s13}
-------------------------------------------------------------------

INS1 cells were transduced with 150 multiplicity of infection of the indicated adenovirus for 48 h total. Glucose concentrations were changed before the last 16 h of culture. CYTO-ID Green (Enzo Life Sciences) was then added at 37°C for 25 min. Nuclei were stained with NucBlue (Molecular Probes), and cells were imaged with a Zeiss Observer Z1 microscope. Autophagy was quantified using a FACSCalibur flow cytometer (BD Biosciences). Reactive oxygen species (ROS) levels were determined using a kit (catalog no. CM-H2DCFDA; Thermo Fisher Scientific) according to the manufacturer's recommendations. TUNEL was assessed using the DeadEND Fluorometric TUNEL System (Promega). Cells were fixed and were stained for TUNEL and insulin (A056401; Dako), and nuclei were identified with DAPI.

ARE-Luciferase Assay {#s14}
--------------------

INS1 cells were transfected with a pGL4.37-luc2p/ARE/Hygro vector (Promega), and a pSV-galactosidase control vector, 24 h after transduction with Ad.ChREBPα. Following experimental incubation, luciferase activity was determined as previously described ([@B11]), and the values were normalized to β-galactosidase activity using a galactosidase assay kit from Promega.

Measurement of Oxygen Consumption Rate {#s15}
--------------------------------------

INS1 cells were transduced with Ad.LacZ or Ad.ChREBPα and after 48 h the oxygen consumption rate (OCR) was determined in a Seahorse XFe96 extracellular flux analyzer. Basal OCR was determined, and OCRs were recorded after the following additions: oligomycin (2.5 μmol/L), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; 1 μmol/L), and rotenone (1 μmol/L) and antimycin A (1 μmol/L).

Metabolomics {#s16}
------------

For metabolomic studies, cell pellets were submitted for liquid chromatography--mass spectrometry module 3 metabolite profiling at the Stable Isotope & Metabolomics Core (Albert Einstein School of Medicine, Bronx, NY), which was done as previously described ([@B20]).

GSIS {#s17}
----

Insulin secretion in response to 5.5 and 20 mmol/L glucose was measured in human islets transduced with Ad.LacZ and Ad.ChREBPα through the use of a previously described method ([@B21]).

Statistics {#s18}
----------

All the data shown are the mean ± SE of results of a number of experiments (indicated in the figure legends). Significance was determined by the unpaired two-way *t* test and one-way ANOVA with the post hoc Tukey honestly significant difference test. Differences were considered significant if the *P* value was \<0.05.

Results {#s19}
=======

ChREBPα Reprograms Metabolism and Promotes Mitochondrial Biogenesis {#s20}
-------------------------------------------------------------------

Some controversy exists in the literature about the role of ChREBP in β-cells. Several studies suggested that ChREBP is at least partially responsible for glucose toxicity ([@B12],[@B22]--[@B24]). Thus, we were initially surprised that ChREBPα overexpression augments glucose-stimulated β-cell proliferation without apparent cytotoxicity ([@B4]). We believe that this can be explained by the recent discovery of ChREBPβ, an alternatively spliced isoform that lacks the low glucose inhibitory domain and nuclear export signals, is constitutively nuclear, and is constitutively and potently active ([@B10]) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). ChREBPβ is induced by a ChoRE. Thus induction of the β isoform initiates an autoregulated feed-forward loop. We recently demonstrated that induction of ChREBPβ is necessary for glucose-stimulated proliferation of rat β-cells ([@B11]). However, apoptosis results when ChREBPβ is overexpressed in β-cells at a level that is many fold higher than physiological levels ([@B12]) ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Together, these observations suggest that physiological induction of the potent ChREBPβ isoform is necessary for adaptive β-cell expansion, but that too much for too long, as may happen from prolonged hyperglycemia in diabetes, or through overexpression with viral vectors, is harmful to β-cells. By contrast, ChREBPα overexpression in INS1 cells or human islets does not stimulate endoplasmic reticulum stress, result in apoptosis, alter ATP-to-ADP ratios, or affect GSIS ([@B13]) ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)), but it does amplify glucose-stimulated β-cell proliferation ([@B4]).

To place the effects of ChREBPα in context with what we know about ChREBPβ, we tested whether ChREBPβ is required for ChREBPα overexpression to have an effect. Islets were isolated from floxed ChREBPβ mice, were treated with Ad.ChREBPα or Ad.GFP as a control, and were cotreated with Ad.Cre recombinase or a control ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Treatment with Cre effectively removed exon 1b, depleting ChREBPβ while allowing ChREBPα to be expressed. Control islets cultured in 20 mmol/L glucose displayed increased proliferation in insulin-positive cells, an effect that was significantly diminished after depletion of ChREBPβ, in accordance with our previous findings ([@B11]). As expected, islets transduced with the ChREBPα adenovirus exhibited amplification of glucose-stimulated β-cell proliferation. When islets were treated with both Ad.ChREBPα and Ad.Cre, proliferation was reduced to basal levels. It is interesting to note that treatment with ChREBPα, which increased ChREBPα levels many fold ([Fig. 1](#F1){ref-type="fig"}), only increased ChREBPβ levels by ∼80% and did not increase levels of several known ChREBP target genes including *Pklr*, *Glut2*, and *Txnip* ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Thus the effects of ChREBPα on glucose-stimulated β-cell proliferation require ChREBPβ without hyperactivation of ChREBP target genes. These results suggest that other signaling pathways must be involved in the augmentation of proliferation when ChREBPα is overexpressed.

![ChREBPα increases anabolic metabolites and β-cell mitochondrial content. *A*: INS1 cells were treated with Ad.ChREBPα or Ad.LacZ (for 48 h) and 2 or 20 mmol/L glucose (Glu) (for 20 h), and cell extracts were prepared for immunoblotting (left; lanes shown are from the same blot with the same exposure) and metabolomic analysis (see also [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). The schema to the right represents the metabolites (purple) that were significantly increased in response to ChREBPα. Metabolites underlined and in italics were increased even in low glucose. OAA, oxaloacetate; PPP, pentose phosphate pathway. *B*: Total intracellular ATP content from INS1 cells was determined and normalized to protein content; values are shown as a percentage of the control (stimulated with 2 mmol/L glucose and treated with Ad.LacZ). *C*: Mitochondrial DNA (mito-DNA) content was determined from INS1 cells through the use of quantitative real-time PCR and normalized to genomic DNA content. *D*: INS1 cells were cotransduced with a baculovirus expressing mitochondria-targeted red fluorescent protein (Mito-RFP) with either Ad.LacZ or Ad.ChREBPα and were treated as indicated. Scale bars = 10 μm. *E*: Signal intensities from the images in *D* relative to the control (treated with low glucose). The values shown are the mean ± SE (*n* = 3--5). \**P* \< 0.05; \*\**P* \< 0.01. arb., arbitrary; MFI, mean fluorescence intensity.](db170943f1){#F1}

Because all proliferating cells require metabolic reprogramming ([@B25]), we examined how ChREBPα affects intermediary metabolism. INS1 cells ([@B17]) were transduced with a control adenovirus, or one expressing ChREBPα, and cultured in 2 or 20 mmol/L glucose. A metabolomic analysis was performed, the results of which are shown in [Fig. 1*A*](#F1){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1). As expected, we found that 20 mmol/L glucose increased the abundance of glycolytic products including glucose-6-phosphate, fructose 1, 6-bisphosphate, glycerol-3-phosphate, pyruvate, and lactate. It is remarkable that ChREBPα treatment further increased their levels. In a similar way, 20 mmol/L glucose increased amounts of the pentose phosphate pathway intermediates 6-phospho-[d]{.smallcaps}-gluconate and ribose-5-phosphate, and ChREBPα increased them further. In addition, the same pattern was seen with the tricarboxylic acid (TCA) cycle intermediates succinate, fumarate, and malate. Furthermore, whereas aspartate levels were not increased by glucose alone, aspartate increased after treatment with ChREBPα and both low and high glucose ([Fig. 1*A*](#F1){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Many of the metabolites in these pathways increased significantly with ChREBPα treatment, even in 2 mmol/L glucose ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)), suggesting increased anaplerotic flux. The increased TCA cycle intermediates suggest an increase in mitochondrial activity. Accordingly, in ChREBPα-treated cells in 2 mmol/L glucose we found a significant increase in ATP ([Fig. 1*B*](#F1){ref-type="fig"}) that was equivalent to that of control cells in 20 mmol/L glucose; however, we found no change in ATP-to-ADP ratios ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). These collective results demonstrate that ChREBPα increases the glycolytic pentose pathway and TCA cycle intermediates, with a high capacity to generate ATP---a metabolic signature of proliferating cells ([@B25],[@B26]).

To explore further the effect of ChREBPα on mitochondria, we measured mitochondrial DNA content and found that it significantly increased in response to glucose. Treatment with ChREBPα increased mitochondrial DNA in both low and high glucose ([Fig. 1*C*](#F1){ref-type="fig"}). Mitochondria were initially visualized by cotransducing a baculovirus expressing mitochondria-targeted red fluorescent protein with either Ad.LacZ or Ad.ChREBPα in INS1 cells.; images of fluorescent cells were acquired by confocal microscopy ([Fig. 1*D*](#F1){ref-type="fig"} and [Supplementary Fig. 4*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Mitochondria appeared as small rods in control cells treated with high glucose. By contrast, mitochondria in ChREBPα-treated cells were tubular and fluoresced brightly. The fluorescent signal intensity in ChREBPα-treated cells was approximately twofold higher than that in control cells ([Fig. 1*D*](#F1){ref-type="fig"} and *E*). Flow cytometric analysis provided similar results ([Supplementary Fig. 4*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)).

To test whether ChREBPα affects mitochondrial function, we stained INS1 cells with tetramethylrhodamine ethyl ester (TMRE) as a measure of mitochondrial transmembrane potential (∆ΨM) ([@B27]). ChREBPα significantly increased ∆ΨM in INS1 cells ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). ChREBPα-treated cells displayed larger, more elongated mitochondria. In addition, when cells preloaded with TMRE were treated with FCCP, a proton ionophore that depolarizes the mitochondrial membrane ([@B27]), the loss of the TMRE label was significantly and proportionately reduced in both LacZ- and ChREBPα-treated cells ([Fig. 2*B*](#F2){ref-type="fig"}). Thus ChREBPα-treated cells have more mitochondrial content with increased ∆ΨM than do control cells.

![ChREBPα enhances mitochondrial oxidative metabolism. *A*: INS1 cells were treated as indicated and cultured in 11 mmol/L glucose. Mitochondrial membrane potential was determined by TMRE labeling and confocal microscopy. Scale bars = 14 μm. *B*: The intensity of individual cells in images acquired by confocal microscopy (as shown in *A*) were quantified with ImageJ software. arb., arbitrary; MFI, mean fluorescence intensity. *C*: The OCR of INS1 cells cultured in 11 mmol/L glucose was measured using a Seahorse XFe96 analyzer. Oligo, oligomycin; R/A, rotenone and antimycin A. *D--G*: Graphs show basal respiration (*D*); maximal respiratory capacity (*E*) (calculated as the difference between FCCP-induced OCR and OCR after addition of the R/A mixture; OCR by nonmitochondrial organelles); the difference between basal OCR and the oligomycin-insensitive OCR (*F*), which is the OCR coupled to ATP synthesis; and the spare respiratory capacity (*G*), calculated by subtracting basal OCR from FCCP-induced OCR. The data shown are the mean ± SE (*n* = 3 or 4). \**P* \< 0.05, \*\*\**P* \< 0.001.](db170943f2){#F2}

To test the oxidative capacity of mitochondria, we measured the OCR. ChREBPα significantly enhanced basal and maximal respiratory capacity (FCCP-induced OCR), and OCR coupled to ATP synthesis (basal OCR -- OCR uncoupled by oligomycin) ([Fig. 2*C*--*F*](#F2){ref-type="fig"}). These findings were consistent with the increased ATP levels in ChREBPα-treated cells ([Fig. 1*B*](#F1){ref-type="fig"}). It is notable that spare respiratory capacity (FCCP-induced OCR − basal OCR) in ChREBPα-treated cells was similar to that of control cells ([Fig. 2*G*](#F2){ref-type="fig"}). Thus, the increased capacity for ATP generation was not associated with overt mitochondrial dysfunction ([@B28]).

To assess whether ChREBPα affects mitochondria in human β-cells, we labeled dispersed human islet cells with MitoTracker Red CMXRos, whose accumulation is dependent on membrane potential ([@B29]), and an antibody against insulin ([Fig. 3*A*](#F3){ref-type="fig"} and [Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Remarkably, glucose increased the MitoTracker signal in human β-cells, and ChREBPα increased it further ([Fig. 3*A* and *B*](#F3){ref-type="fig"} and [Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). In addition, ATP levels were increased by glucose in control cells, and in ChREBPα-treated human islets in low glucose ([Fig. 3*C*](#F3){ref-type="fig"}). These data collectively demonstrate that ChREBPα increases mitochondrial size and activity in both rodent and human β-cells.

![ChREBPα increases β-cell mitochondrial activity and ATP production in human islets. *A*: Dispersed human islets were transduced with the indicated adenovirus, treated as shown, and labeled with MitoTracker Red CMXRos (Mito) and an anti-insulin antibody (ins). Scale bars = 20 μm. *B*: The mitochondrial signal intensity was determined from the images in *A* and is shown relative to the control (treated with low glucose \[Glu\]). *C*: Total intracellular ATP content was determined in human islets and normalized to protein content. Data are shown as a percentage of the control (stimulated with low Glu and treated with Ad.LacZ). The values shown are the mean ± SE (*n* = 3--5). \**P* \< 0.05, \*\**P* \< 0.01. MFI, mean fluorescence intensity.](db170943f3){#F3}

ChREBPα Activates the Antioxidant Nrf2 Pathway {#s21}
----------------------------------------------

To understand better the mechanism by which ChREBPα increases mitochondrial activity, we tested whether ChREBPα increased the expression of known mediators of mitochondrial activity and biogenesis. As shown in [Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1), mRNA levels of PGC1α were not changed. PGC1β mRNA levels were modesty increased, but ChREBPα had no effect on PGC1β protein levels. In addition, levels of Tfam, Polrmt, Tfb1m, Tfb2m, and Polg mRNA did not significantly change with ChREBPα treatment. Nrf2 is a master regulator of antioxidant pathways, and its activation is often associated with increased mitochondrial activity ([@B14],[@B15],[@B30]--[@B32]). ChREBPα substantially increased Nrf2 protein abundance in both 2 and 20 mmol/L glucose ([Fig. 4*A* and *B*](#F4){ref-type="fig"}), but it did not change mRNA levels ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)), suggesting regulation at a posttranslational level. Furthermore, Nrf2 abundance was clearly increased and was localized in the nucleus and cytoplasm after treatment with ChREBPα, as indicated by immunofluorescence ([Fig. 4*C*](#F4){ref-type="fig"}). As shown in [Fig. 4*D*](#F4){ref-type="fig"}, glucose increased ARE-driven luciferase activity in control cells, suggesting that activation of Nrf2 is a natural component of the glucose response in β-cells. ChREBPα enhanced ARE activity in both low and high glucose concentrations. We note that because Nrf2 abundance did not increase with glucose ([Fig. 4*B*](#F4){ref-type="fig"}), there may be Nrf2-independent mechanisms through which glucose increases ARE activity. In addition, we found that ChREBPα upregulated the antioxidant enzymes H01 and Nq01, as well as the mitochondrial biogenic transcription factor Nrf1 ([Fig. 4*E*](#F4){ref-type="fig"}). At the protein level, ChREBPα also increased Nrf1, which contains an ARE and is downstream from Nrf2 ([@B33]) ([Fig. 4*F*](#F4){ref-type="fig"}). Thus, ChREBPα activates the Nrf2 pathway.

![ChREBPα activates the Nrf2 pathway. *A*: Immunoblots of extracts from INS1 cells treated as shown. The lanes shown here are from noncontiguous lanes on the same blot with the same exposure. *B*: Quantification of densitometry from the immunoblots in *A*. *C*: INS1 cells cultured in 11 mmol/L glucose (Glu) were treated with the indicated adenovirus and were fixed and stained with antibodies against Nrf2 and Flag. Scale bars = 20 μm. *D*: INS1 cells were treated as indicated, and luciferase activity was measured in cell extracts and normalized to β-galactose (β-Gal) activity. *E*: The abundance of mRNA relative to β-actin in the indicated genes was measured by RT-PCR. *F*: Immunoblots with antibodies against Nrf1 and actin. The noncontiguous lanes shown are from the same blot with the same exposure (see also [Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Data are the mean ± SE (*n* = 4). \**P* \< 0.05; \*\**P* \< 0.01.](db170943f4){#F4}

Activation of Nrf2 Is Essential for Glucose-Stimulated β-Cell Proliferation and for ChREBPα-Augmented Mitochondrial Biogenesis and Proliferation {#s22}
------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether Nrf2 is required for glucose-stimulated β-cell proliferation or ChREBPα-mediated mitochondrial biogenesis, we first used an siRNA knockdown approach. Nrf2 abundance was modestly decreased by siRNA in INS1 cells ([Fig. 5*A*](#F5){ref-type="fig"}). Depletion of Nrf2 blocked glucose-stimulated β-cell proliferation of INS1 cells under control conditions. In addition, decreasing Nrf2 inhibited ChREBPα-augmented glucose-stimulated proliferation ([Fig. 5*B*](#F5){ref-type="fig"}). Furthermore, suppression of Nrf2 resulted in diminished mitochondrial membrane potential, as determined by TMRE labeling, both under control conditions and after treatment with ChREBPα ([Fig. 5*C* and *D*](#F5){ref-type="fig"}).

![Knockdown of Nrf2 decreases mitochondrial activity and glucose (Glu)-stimulated β-cell proliferation. *A*: Immunoblots of extracts from INS1 cells cultured in 11 mmol/L Glu and treated with control siRNA or scrambled siRNA (siScr). Nrf2 was decreased ∼30%, as determined by densitometry. *B*: Proliferation of INS1 cells was determined through the use of BrdU staining. *C*: INS1 cells were treated as indicated and were labeled with TMRE. Scale bars = 10 μm. *D*: Results from the TMRE labeling (as shown in *C*) were quantified. *E*: Immunoblots of human islet extracts were treated as indicated. Nrf2 was decreased ∼20% and ∼30% in GFP- and ChREBPα-treated islets, respectively. *F*: Dispersed human cells were fixed and stained for insulin and Ki67. Results are the mean ± SE (*n* = 3) of the percentage of Ki67- and insulin-positive cells. \**P* = 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. arb., arbitrary; MFI, mean fluorescence intensity.](db170943f5){#F5}

To determine whether Nrf2 was required for human β-cell proliferation, human islet cells were treated with pooled lipid-conjugated Accell siRNA, which knocks down genes in human islet cells without toxicity and preserves glucose-mediated proliferation ([@B4]). Treatment with Accell siRNA against Nrf2 resulted in a modest decrease in Nrf2 protein levels ([Fig. 5*E*](#F5){ref-type="fig"}). Remarkably, depletion of Nrf2 in human β-cells diminished glucose-stimulated proliferation of both control cells and β-cells whose glucose response was augmented by ChREBPα treatment ([Fig. 5*E* and *F*](#F5){ref-type="fig"}). Together, these experiments show for the first time that Nrf2 is necessary for normal glucose-stimulated proliferation and for ChREBPα-augmented glucose-stimulated proliferation of rodent and human β-cells.

Nrf2 is regulated by its interaction with Keap1, a substrate adaptor protein for a Cul3-containing E3 ligase that maintains Nrf2 at low levels through polyubiquitination and proteasomal degradation ([@B34],[@B35]). To confirm the siRNA data, we transduced INS1 cells with an adenovirus expressing human Keap1. As expected, increased Keap1 was accompanied by a reduction of Nrf2 protein levels in both low and high glucose ([Fig. 6*A*](#F6){ref-type="fig"}). Treatment with Keap1 reduced glucose-stimulated ARE-driven luciferase activity in Ad.GFP-treated control cells, consistent with its ability to diminish Nrf2 ([Fig. 6*B*](#F6){ref-type="fig"}). In addition, cells overexpressing Keap1 exhibited poor TMRE labeling ([Fig. 6*C* and *D*](#F6){ref-type="fig"}). Further, Keap1 decreased basal and glucose-stimulated proliferation of INS1 cells, as expected because of the decrease of Nrf2 ([Fig. 6*E*](#F6){ref-type="fig"}). It is surprising that when cells were treated with both Keap1 and ChREBPα, the abundance of Keap1 decreased. Nrf2 abundance consequently increased to levels higher than those stimulated by ChREBPα ([Fig. 6*A*](#F6){ref-type="fig"}). Keap1 had no significant effect on the ChREBPα-mediated increase in ARE activity ([Fig. 6*B*](#F6){ref-type="fig"}). In addition, no Keap1-mediated loss in ∆ΨM occurred when ChREBPα was coexpressed with Keap1 ([Fig. 6*C*](#F6){ref-type="fig"} and *D*). Furthermore, ChREBPα rescued the Keap1-mediated inhibition of proliferation, presumably because Nrf2 downregulation was blocked. Together, these data suggest that overexpression of Keap1 inhibits Nrf2, consistent with the siRNA data presented above ([Fig. 5](#F5){ref-type="fig"}). However, coexpression of ChREBPα and Keap1 led to decreased Keap1 levels and increased Nrf2 abundance, providing a possible explanation for how ChREBPα promotes the induction of Nrf2.

###### 

Keap1 decreases Nrf2, decreasing mitochondrial function and proliferation, whereas ChREBPα decreases Keap1, reversing the effects of Nrf2 depletion. *A*: Immunoblots from extracts of INS1 cells treated as indicated. *B*: INS1 cells were treated as shown, and luciferase activity was measured and normalized to β-galactosidase (β-Gal) activity (mean ± SE). \**P* \< 0.05; \*\**P* \< 0.02. *C*: INS1 cells were treated as indicated and were labeled with TMRE. Scale bars = 14 μm. *D*: Results from the TMRE labeling (shown in *C*) were quantified (mean ± SE). \**P* \< 0.001; \*\**P* \< 0.0001. *E*: Proliferation of INS1 cells was determined through the use of BrdU staining. Data shown are the mean ± SE (*n* = 3 or 4). \**P* \< 0.01; \*\**P* \< 0.001; \*\*\**P* \< 0.0001. *F*: Immunoblots from extracts of human islets that were treated as shown. The arrow indicates Keap1. *G*: Dispersed human islets were labeled with MitoTracker Red CMXRos (Mito). Scale bars = 10 μm. *H*: Quantification of the staining shown in *G*. \*\**P* \< 0.01. *I*: Dispersed human islet cells were fixed and stained for insulin and Ki67. Results are a percentage of Ki67- and insulin-positive cells. Data shown are the mean ± SE (*n* = 5). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. arb., arbitrary; Glu, glucose; ins, insulin; MFI, mean fluorescence intensity.

![](db170943f6-1)

![](db170943f6-2)

To determine whether these events were reflective of human β-cell biology, we treated human islet cells with Keap1 or with a combination of Keap1 and ChREBPα ([Fig. 6*F*](#F6){ref-type="fig"}). In human β-cells, Keap1 decreased Nrf2 levels, as expected. Coexpression of ChREBPα reduced the abundance of Keap1 and maintained Nrf2 at levels comparable with those of the control. Furthermore, Keap1 treatment decreased MitoTracker Red CMXRos labeling in human β-cells, in accordance with diminished Nrf2 ([Fig. 6*G* and *H*](#F6){ref-type="fig"}). However, Keap1 only slightly attenuated the dramatic increase in MitoTracker labeling that occurred after treatment with ChREBPα. In addition, Keap1 inhibited basal and glucose-stimulated β-cell proliferation in human islets ([Fig. 6*I*](#F6){ref-type="fig"}), in agreement with the Nrf2 siRNA data ([Fig. 5](#F5){ref-type="fig"}). It is important to note that coexpression with Keap1 and ChREBPα prevented this effect ([Fig. 6*I*](#F6){ref-type="fig"}), in concert with the results shown in [Fig. 5](#F5){ref-type="fig"}. Taken together, these data suggest that Nrf2 is essential for glucose-simulated β-cell proliferation.

Overexpression of Nrf2 Is Sufficient to Drive Human β-Cell Proliferation {#s23}
------------------------------------------------------------------------

To test whether overexpression of Nrf2 affects β-cell proliferation, we dispersed human islet cells and transduced them with either control Ad.LacZ or Ad.Nrf2 ([Fig. 7](#F7){ref-type="fig"}). Cells were cultured for 16 h with low glucose (2 or 6 mmol/L) or high glucose (20 mmol/L) and were fixed and immunostained for insulin and Ki67. As expected, 20 mmol/L glucose increased Ki67 staining in control cells by approximately twofold. It is surprising, however, that Nrf2 overexpression resulted in an approximately ninefold increase in human β-cells at the low glucose conditions and displayed a fourfold increase of proliferation with high glucose---equivalent to that in the control high-glucose group. These proliferative effects did not alter cell death, as shown in [Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1). Thus, exogenous expression of Nrf2 is sufficient to drive human β-cell proliferation.

![Exogenous Nrf2 is sufficient to drive proliferation of human β-cells. Dispersed human islets were transduced with the indicated adenoviruses for a total of 48 h. Cells were cultured in either 2 or 6 mmol/L glucose (low glucose) or 20 mmol/L glucose (high glucose). The high glucose was added for the last 16 h of the experiment. *A*: Cells were fixed and immunostained for insulin and Ki67; these results are quantified in *B*. Scale bars = 40 μm. Data are the mean ± SE of the percentage of cells that were both Ki67- and insulin (INS)-positive (*n* = 6). \**P* \< 0.05.](db170943f7){#F7}

![Model of ChREBPα-mediated activation of the Nrf2 and anabolic pathways driving β-cell proliferation. ChREBPα inhibits Keap1 activity, contributing to an increase in Nrf2 abundance. Nrf2 binds to AREs, which drives expression of antioxidant and metabolic enzyme genes. Mitochondrial biogenesis and activity increase, resulting in increased ATP production and anabolic metabolism. A potential feedback loop contributes to the maintenance of the anabolic state, whereby electrophiles inhibit Keap1-Nrf2 interaction through the disruption of cysteine residues. Increased ATP production and anabolic metabolism contribute to increased glucose-stimulated β-cell proliferation.](db170943f8){#F8}

Discussion {#s24}
==========

Here we show that activation of the Nrf2 pathway is required for normal and ChREBPα-enhanced glucose-stimulated rodent and human β-cell proliferation. Increased Nrf2 abundance was associated with enhanced anabolic activity, including increased anabolic metabolites, increased mitochondrial content and activity, and increased glucose-stimulated proliferation ([Fig. 8](#F8){ref-type="fig"}).

Using loss- and gain-of-function experiments, we showed that ChREBP is required for glucose-stimulated β-cell proliferation and that overexpression of ChREBP amplified the effect of glucose on proliferation, without apparent ill effects ([@B4]). We also recently demonstrated that the feed-forward induction of the newly identified ChREBPβ isoform is necessary for glucose-stimulated β-cell proliferation ([@B11]). These results were surprising in the face of numerous studies implicating ChREBP in glucose toxicity ([@B12],[@B22]--[@B24]). In the current study, however, direct comparison of ChREBPα and ChREBPβ overexpression in β-cells demonstrated that apoptosis results when ChREBPβ is expressed to levels many fold higher than physiological levels, an observation consistent with a previous report ([@B12]). By contrast, ChREBPα overexpression in INS1 cells or human islets does not affect GSIS and does not result in apoptosis, observations congruent with those of Wang et al. ([@B13]). Together these observations suggest that physiological induction of the potent, constitutively active, nuclear ChREBPβ isoform is necessary for adaptive β-cell expansion, but that too much for too long, as may happen from prolonged hyperglycemia in diabetes ([@B12]) or through overexpression with viral vectors, is harmful to β-cells. In addition, because treatment with ChREBPα exerts a positive effect on β-cell anabolism and proliferation, and initiates an antioxidant pathway, therapies that adjust the ratio between ChREBPα and ChREBPβ may be beneficial to patients with diabetes who have insufficient β-cell mass. It is interesting that Shalev and colleagues ([@B36]) found that ChREBPβ and ChREBPα oppose each other's effects. Those authors demonstrated that ChREBPβ overexpression decreases ChREBPα abundance, and they postulated that the role of ChREBPβ is to prevent ChREBPα from mediating glucose toxicity. Those experiments were performed within relatively short time frames and did not assess apoptosis. Further experiments are needed to resolve these differences and to test the effects of each isoform on the activity of the other with respect to proliferation, apoptosis, and function.

ChREBPα increased Nrf2 in both rodent and human β-cells, providing an explanation for the augmented anabolic response of ChREBPα in the absence of apoptosis. In its basal state, Nrf2 is tightly bound by Keap1, an adaptor protein that brings a Cullin3-Rbx1 E3 ligase complex into close proximity to Nrf2, leading to rapid ubiquitination and degradation of Nrf2 in proteasomes ([@B34],[@B35]). Upon alkylation, oxidation, or conformational change, Keap1 has a reduced affinity for Nrf2, relieving its ubiquitination and degradation. Nrf2 is then free to migrate to the nucleus and activate AREs in the regulatory regions of target genes. An important target of Nrf2 is Nrf1, which---along with PGC family members---activates AREs that drive mitochondrial biogenesis ([@B37]). Other important targets of Nrf2 include antioxidant enzymes such as heme oxygenase-1, NAD(P)H dehydrogenase, and quinone 1, and induction of these enzymes is closely associated with the role of Nrf2 in protection against oxidative stress ([@B31]). Chromatin immunoprecipitation sequencing studies have identified hundreds of Nrf2 gene targets ([@B38],[@B39]). In addition to antioxidant genes, these include numerous genes involved in intermediary metabolism, including the pentose phosphate pathway, providing reducing equivalents that are useful for antioxidant enzymes and are building blocks for proliferation ([@B32],[@B33]). It follows that Nrf2 also promotes increased mitochondrial function ([@B30]).

To our knowledge, this study is the first to demonstrate that Nrf2 is required for glucose-stimulated β-cell proliferation and, when overexpressed, is sufficient to drive human β-cell proliferation. The role of Nrf2 in β-cells has only recently been explored, and research has been largely restricted to its antioxidant properties. Abebe et al. ([@B40]) recently found that female Zucker fatty rats recovering from a short-term high-fat diet have β-cell function and morphology largely restored through the Nrf2 pathway. Furthermore, Uruno et al. ([@B41]), using a global Keap1^+/−^ knockout mouse on a db/db genetic background, demonstrated that activation of the Nrf2 pathway prevented diabetes, in part by preserving β-cell mass. Yagishita et al. ([@B42]) demonstrated that activation of Nrf2 protects β-cells from the stress of inducible nitric oxide synthase overexpression in mice. Masuda et al. ([@B43]) transplanted human islets into mice after treatment with an Nrf2 activator. Unfortunately, that study only examined the proportion of mice rescued from hyperglycemia after islet transplantation and found no difference from the controls. That study did not test rates of human β-cell survival immediately after transplantation into euglycemic or diabetic mice. The same group found that Nrf2 activation improved rat islet transplantation outcomes ([@B44]), but the same analysis has not been done with human islets. Horn et al. ([@B45]), using a bioinformatics approach, identified Nrf2 among a set of transcription factors that mediate adaptive expansion of β-cell mass, including Myc, Mycn, Hnf1α, Hnf4α, and E2f1. How might Nrf2 mediate β-cell proliferation? Nrf2 activates antioxidant genes as well as genes of the pentose phosphate pathway, presumably in order to generate NADPH to restore antioxidant enzyme redox balance ([@B14]). In addition, NADPH is an important reducing equivalent for lipogenesis and DNA synthesis, which are crucial for proliferating cells ([@B25]). Thus, activation of Nrf2 may serve a dual role in β-cell proliferation: as an inducer of antioxidant enzymes and in support of the anabolic production of biomass before cytokinesis.

Balancing ROS production with protection against ROS may be critical for β-cell function and survival. Some ROS are necessary for maximal GSIS in β-cells ([@B46],[@B47]). Thus, it has been argued that increasing Nrf2 in β-cells, associated with increased antioxidant activity, may inhibit the ROS production that supports GSIS ([@B48]). In the current study, however, we found that ChREBP distinctly imparts antioxidant effects via Nrf2 without affecting GSIS ([Supplementary Fig. 2*E*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). It is important to note that our observations show that induction of Nrf2 is not a result of oxidative or endoplasmic reticulum stress, because the classic stress markers Atf3 and C/EBP homologous protein were not induced in ChREBPα-treated β-cells. We also found that ChREBPα does not alter ROS levels ([Supplementary Fig. 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Thus, in our study, ChREBPα increased mitochondrial and anabolic activities, with their attendant increase in ROS production, but this is countered by activation of Nrf2 and increased antioxidant enzyme production.

Keap1 and Nrf2 interact with each other and with other proteins. One important interaction that might at least partly explain our results is the interaction between Keap1 and p62, the regulator of autophagy ([@B49]). Activation of autophagy or mitophagy might stimulate mitochondrial biogenesis. Therefore, we tested whether overexpression of ChREBPα or Nrf2 activated autophagy ([Supplementary Fig. 9](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1)). Glucose, ChREBPα, and Nrf2 all decreased autophagosome labeling. Furthermore, the expression of autophagy genes generally decreased, with the exception of *Ulk1*, which was increased in response to Nrf2. Thus, ChREBPα does not activate autophagy, but further experiments should be performed to clarify how Nrf2 overexpression interacts with autophagy pathways.

A limitation of our study is that we did not identify the mechanism(s) through which ChREBPα inhibits Keap1. Attempts at coimmunoprecipitation of ChREBPα and Keap1 were unsuccessful (data not shown). Another limitation of our study is that the metabolic analysis was cross-sectional. While our results are consistent with those from an anabolic cell that is primed for proliferation, a more longitudinal approach or one that uses isotopomeric substrates to analyze changes in metabolic fluxes as the cells transition from a quiescent to a proliferative state would be more revealing. Future studies will focus on the precise molecular mechanisms through which ChREBPα and Nrf2 alter β-cell metabolism and phenotype.

In summary, we explored the mechanisms through which ChREBPα amplifies glucose-stimulated proliferation of rodent and human β-cells. We found that ChREBPα reduces Keap1 abundance, activating Nrf2, a transcription factor that initiates genetic programs of antioxidant protection, mitochondrial biogenesis, and anabolic metabolism. We found that the induction of Nrf2 was required for normal and for ChREBPα-augmented β-cell proliferation. Dissecting ChREBPα- and Nrf2-driven anabolic pathways should provide new opportunities for designing β-cell regenerative therapies.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0943/-/DC1>.
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